Search results
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 13 hours agoBut in newborns and older adults it can be serious or even deadly. Moderna will rival Pfizer and...
Moderna shares rise as Argus lifts price target to $150 By Investing.com
Investing.com· 12 hours agoThe firm's decision follows the U.S. Food and Drug Administration's (FDA) approval of Moderna's...
Moderna stock is lone omen of bird flu pandemic
Reuters· 3 days agoThe recent rise of Moderna’s stock tells a grim tale. The $56 billion company which pioneered a Covid vaccine has seen its market value rise 40% since...
Moderna Stock (NASDAQ:MRNA): Is There Life Beyond Disease Outbreaks?
TipRanks via Yahoo Finance· 3 days agoModerna (NASDAQ:MRNA) stock has surged 40.8% since the turn of the year. Some of this momentum can...
Gateway - Quartz
Quartz· 2 days agoLike many other wealthy nations, the country bought many more vaccines than it needed—a total of nearly 32 million—to account for potential quality issues, or supply delays ...
Feeling Sick After Your COVID Vaccine? According to Scientists, It’s Actually a Good Sign
SciTechDaily· 2 days agoA UCSF study suggests that side effects like headaches and chills from COVID-19 vaccines indicate a...
Column: This GOP-leaning political polling firm has turned into a purveyor of anti-vaccine...
LA Times via Yahoo News· 2 days agoBlaming the COVID vaccines for a tide of undocumented injuries and deaths is a popular theme in the...
Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Zacks via Yahoo Finance· 15 hours agoIntra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight...
Novavax seeks FDA nod for updated COVID-19 vaccine By Investing.com
Investing.com· 7 days agoFood and Drug Administration (FDA) for its updated JN.1 COVID-19vaccine, NVX-CoV2705, for...
...NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company's Next-Generation...
NewMediaWire via Yahoo Finance· 3 days ago10,000-participant randomized Phase 2b study will evaluate and compare GeoVax's multi-antigen, ...
